Drug Trial Radar · NCT07794475
Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Sara Refaat Azab MetryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate if trimetazidine can improve clinical outcomes of patients with diabetic peripheral neuropathy. The main questions it aims to answer are: Does trimetazidine improve the symptoms of diabetic peripheral neuropathy? Does trimetazidine affect endothelin-1 levels? Participants in the interventional arm will receive trimetazidine tablets 35 mg twice daily for three months.
Conditions
- Diabetic Peripheral Neuropathic Pain (DPN)
Interventions
Trimetazidine Dihydrochloride TabletsDrug
trimetazidine 35 mg oral tablets twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endothelin-1 levelsTime frame: at baseline assessment and at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Diabetes
Cairo, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.